Effects of re-challenge with temozolomide in grade 2/3 IDH mutant gliomas at first progression.

ABSTRACT:

Background

Patients with WHO grade 2 and 3 isocitrate dehydrogenase mutation (IDHmt) gliomas commonly receive temozolomide (TMZ), with or without radiation therapy, as initial therapy. At progression, TMZ is sometimes reinstated despite a paucity of data on effectiveness.

Methods

We reviewed imaging outcomes of patients with WHO 2016 grade II/III IDHmt gliomas re-treated with TMZ at first progression between 2007 and 2019. Tumor growth rates were calculated over the year preceding re-treatment and throughout the re-treatment period, ranging from 3 to 41 months. RANO criteria were utilized to assess TMZ response rate.

Results

15 subjects included six grade II, five grade III oligodendrogliomas, one grade II and three grade III astrocytomas. Median time between completi

SUBMITTER: Yogendran LV 

PROVIDER: S-EPMC12511160 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature